公开(公告)号：US09796754B2

公开(公告)日：2017-10-24

申请号：US14122672

申请日：2012-05-24

申请人： Zhenwei Miao ,  Kyle Atkinson ,  Sandra Biroc ,  Timothy Buss ,  Melissa Neal ,  Vadim Kraynov ,  Robin Marsden ,  Jason Pinkstaff ,  Lillian Skidmore ,  Ying Sun ,  Agnieszka Szydlik ,  Delia Ianina Lopez De Valenta

发明人： Zhenwei Miao ,  Kyle Atkinson ,  Sandra Biroc ,  Timothy Buss ,  Melissa Neal ,  Vadim Kraynov ,  Robin Marsden ,  Jason Pinkstaff ,  Lillian Skidmore ,  Ying Sun ,  Agnieszka Szydlik ,  Delia Ianina Lopez De Valenta

IPC分类号： A61K38/00 ,  A61P35/00 ,  C07K5/103 ,  C07D207/08 ,  C07D401/12 ,  C07D417/12 ,  A61K47/48 ,  C07K5/02 ,  A61K38/07 ,  C07K5/062

CPC分类号： C07K5/101 ,  A61K38/07 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6849 ,  A61K47/6855 ,  A61K47/6861 ,  C07D207/08 ,  C07D401/12 ,  C07D417/12 ,  C07K5/0205 ,  C07K5/06043

摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.